CNS Pharmaceuticals Inc
NASDAQ:CNSP
CNS Pharmaceuticals Inc
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. The company is headquartered in Houston, Texas and currently employs 3 full-time employees. The company went IPO on 2019-11-08. The firm is focused on development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The firm is developing its lead drug candidate, Berubicin for the treatment of glioblastoma. Glioblastoma are tumors that arise from astrocytes, which are star-shaped cells making up the supportive tissue of the brain. Berubicin is an anthracycline, a class of drugs that are among the chemotherapy drugs, which intercalates into Deoxyribonucleic acid (DNA) and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, and RNA and protein synthesis. The firm is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents.
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. The company is headquartered in Houston, Texas and currently employs 3 full-time employees. The company went IPO on 2019-11-08. The firm is focused on development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The firm is developing its lead drug candidate, Berubicin for the treatment of glioblastoma. Glioblastoma are tumors that arise from astrocytes, which are star-shaped cells making up the supportive tissue of the brain. Berubicin is an anthracycline, a class of drugs that are among the chemotherapy drugs, which intercalates into Deoxyribonucleic acid (DNA) and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, and RNA and protein synthesis. The firm is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents.
IPO & Cash Runway: CNS Pharmaceuticals completed its IPO in November 2019, raising $9.8 million and ending the year with $7.2 million in cash, providing runway into mid-2021.
Lead Drug Progress: The company advanced preparations for a Phase 2 US trial of its lead drug Berubicin for glioblastoma, with initiation targeted for the second half of 2020, pending FDA approval.
FDA Feedback: CNS received positive FDA feedback on using existing Berubicin supply and dosing regimen, aiding the IND submission process.
International Partnerships: Partner WPD Pharmaceuticals is set to conduct parallel Phase 2 and pediatric Phase 1 trials in Poland, supported by a $6 million grant.
Second Pipeline Asset: CNS licensed a second drug candidate, WP1244, showing high potency in preclinical studies, with plans to start preclinical work by year-end.
Expenses: R&D and G&A expenses rose sharply in Q4 as development efforts scaled post-IPO; G&A expected to be $2.5–3.0 million annually.
Additional Capital: Management stated up to $7 million more may be needed to complete the Phase 2 trial.
